Bayer has big plans following Merck OTC deal
8 May 2014
Bayer has agreed to acquire US Merck & Co's Consumer Care business for US$14.2 billion after a "highly-contested quest for a crown jewel", and has big plans for the brands outside the US.
News Extras
OTCToolbox News Extra publications provide you with rapid insights into developments in the consumer healthcare/OTC industry worldwide. They can be purchased and downloaded immediately. They are also available as part of an Annual Subscription to the OTCToolbox website.
GSK and Novartis unveil "unusual" OTC deal
23 April 2014
GlaxoSmithKline and Novartis have agreed to combine their global consumer healthcare operations into a world-leading business with annual sales of £6.5 billion (US$10.9 billion).
US scrutinises OTC monograph process
9 April 2014
A wide range of suggestions for changing the US OTC drug review were put forward by speakers at a recent public hearing organised by the Food and Drug Administration (FDA).
Perrigo expands in US, abroad and online
19 March 2014
Perrigo is expanding outside the US, capitalising on e-commerce through Amazon, entering adjacent product categories, and building value brands as well as store brands.
Private-equity deal highlights Atrium’s ambitions
4 December 2013
News that Canada's Atrium Innovations is set to be acquired by a group of investors, including private-equity firm Permira, shows the ambitions of the dietary supplements company.
Stada strikes two deals in quick succession
22 October 2013
Germany’s Stada Arzneimittel has demonstrated its OTC ambitions by striking two deals in quick succession. Deborah Wilkes reports on the German generics company's business strategy.
Bayer maps route to global top spot in OTC
4 July 2013
Global brand expansion, innovation, emerging market growth and bolt-on acquisitions can make Bayer Consumer Care the world's number one OTC player, says worldwide head Erica Mann.
Thornton & Ross has ambitions outside UK
31 May 2013
German generics company Stada has just acquired Thornton & Ross for €259 million, and plans to turn the UK-based OTC company into a group-wide centre of excellence for OTC products. Produced several months before the Stada deal was agreed, this publication provides an overview of Thornton &...
GlaxoSmithKline reshapes Consumer Healthcare
3 May 2013
GlaxoSmithKline’s decision to divest its Lucozade and Ribena drinks is another step in the company’s strategy of transforming its consumer unit into the world’s “first and best fast-moving consumer healthcare” operation.